Related Experiment Videos
[Role of carboplatin in treating patients with advanced ovarian cancer]
1Kliniki Chemioterapii Centrum Onkologii Oddział Kraków.
Ginekologia Polska
|August 1, 1992
Abstract:
Results of Carboplatin treatment of ovarian cancer were presented. Drug resistance was observed during therapy of first course type. Objective response to treatment was observed with 5 patients from 27 ones (19%).
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
Annals of oncology : official journal of the European Society for Medical Oncology·2011
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Annals of oncology : official journal of the European Society for Medical Oncology·2010
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2008
A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology·2008
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology·2008
Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study.
Cancer chemotherapy and pharmacology·2007
Maternal serum biomarkers and early pregnancy Doppler blood flow patterns.
Ginekologia polska·2026
Enhancing intravesical bladder cancer therapy: from mucoadhesive to targeted drug delivery strategies.
Frontiers in medicine·2026
Bio-based nanophotothermal systems as smart drug delivery platforms for multimodal synergistic cancer therapy-a review.
Frontiers in medical technology·2026